SCHEMBL30680216

SCHEMBL30680216

O=c1c(-c2ccccc2)c(Cn2cnc3ccccc32)oc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 8/20 0.49
CYP11B2 P19099 8/20 0.49
TNF P01375 1/20 0.47
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CYP19A1 P11511 2/20 0.42
PKM P14618 3/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 2/20 0.41
IDO1 P14902 1/20 0.41
EGLN3 Q9H6Z9 1/20 0.40
BRD4 O60885 1/20 0.40
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9083 1.00 CYP11B1 (0.49) CYP11B1CYP11B2TNFCA1CA2
SCHEMBL10907 0.87 CYP11B1 (0.44) CYP11B1CYP11B2TNFPKMLMNA
SCHEMBL29651707 0.87 CYP11B1 (0.44) CYP11B1CYP11B2TNFPKMLMNA
SCHEMBL30680212 0.84 ALDH1A1 (0.46) CYP11B1CYP11B2CA1CA2CYP19A1
SCHEMBL10586 0.84 ALDH1A1 (0.46) CYP11B1CYP11B2CA1CA2CYP19A1
SCHEMBL8786 0.76 MEN1 (0.41) CYP11B1CYP11B2CA1CA2CYP19A1
SCHEMBL29651680 0.76 ADORA2A (0.53) CA1CA2CYP19A1LMNASMN1; SMN2
SCHEMBL8577 0.76 ADORA2A (0.53) CA1CA2CYP19A1LMNASMN1; SMN2
SCHEMBL29651625 0.75 CYP19A1 (0.69) CYP11B1CYP11B2CYP19A1
SCHEMBL8506 0.75 CYP19A1 (0.69) CYP11B1CYP11B2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 EP claimed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 US disclosed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 CYP11B1 4144/4885CYP11B2 4279/4885TNF 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.